McKesson Designated by CMS as 2023 Qualified Clinical Data Registry

Eight custom measures receive approval, impacting value-based oncology care

For the seventh consecutive year, McKesson has received approval from The Centers for Medicare & Medicaid Services (CMS) to participate in the Merit-based Incentive Payment System (MIPS) as a Qualified Clinical Data Registry (QCDR). The designation enables iKnowMed℠ electronic health record (EHR) users to efficiently submit data directly to CMS without engaging a separate registry vendor, streamlining data submission and minimizing administrative burden.

As a CMS-approved QCDR, Practice Insights℠, a performance analytics tool powered by Ontada^®, can collect and report clinical data on behalf of clinicians for standard MIPS with the additional ability to report on custom QCDR quality measures to drive improvements in quality and cost of care.

“We are committed to delivering industry-leading solutions that enable community oncology to efficiently meet the challenges value-based care presents,” said Susan Shiff, president, Ontada. “Having Practice Insights named an approved QCDR is a critical part of this ongoing effort. This powerful analytics tool creates a holistic roadmap that supports the clinical, financial, and operational needs of practices, providing actionable insights that drive improved outcomes and enable them to assess performance across value-based initiatives.”

Six custom QCDR measures identified by physician leaders in The US Oncology Network (The Network) and submitted by McKesson were approved by CMS. Additionally, CMS approved two custom measures developed by the American Society of Clinical Oncology (ASCO) that will also be supported by McKesson’s QCDR. Combined, they include:

• Advance Care Planning in Metastatic Cancer Patients
• Hepatitis B Serology Testing and Prophylactic Treatment Prior to Receiving Anti-CD20 Targeting Drugs
• Mutation Testing for Stage IV Lung Cancer Completed Prior to the Start of Targeted Therapy
• Patient-Reported Pain Improvement
• Supportive Care Drug Utilization in Last 14 Days of Life
• Utilization of GCSF in Metastatic Colorectal Cancer (Also included in the Advancing Cancer Care MVP)
• Antiemetic Therapy for Low- and Minimal-Emetic-Risk Antineoplastic Agents in the Infusion Center - Avoidance of Overuse (Developed by ASCO)
• Appropriate Antiemetic Therapy for High- and Moderate-Emetic-Risk Antineoplastic Agents in the Infusion Center (Developed by ASCO)

“While this is the seventh straight year McKesson has gained approval for its oncology-specific QCDR, this year is different from the past as McKesson collaborated with ASCO on several fronts to drive innovation and improved care for oncology patients,” said Erin Crum, director of Quality Portfolio Strategy, McKesson. “In addition to our collaboration on the QCDR measures, we also worked with ASCO to develop an oncology-specific MIPS Value Pathway (MVP) proposal to present to CMS. Collaborating with ASCO to send recommendations for CMS’s final 2023 Advancing Cancer Care MVP was a significant honor. We are proud of what we’ve been able to do together to push cancer care forward.”

Along with The US Oncology Network, McKesson also supports oncology practices through its Onmark^® group purchasing organization (GPO), and the QCDR measure approvals reflect the organization’s insight into the entire landscape of oncology care.

About McKesson Corporation

McKesson Corporation is a diversified healthcare services leader dedicated to advancing health outcomes for patients everywhere. Our teams partner with biopharma companies, care providers, pharmacies, manufacturers, governments, and others to deliver insights, products, and services to help make quality care more accessible and affordable. Learn more about how McKesson is impacting virtually every aspect of healthcare at McKesson.com and read Our Stories.

About The US Oncology Network

Every day, The US Oncology Network (The Network) helps more than 2,000 independent providers deliver value-based, integrated care to patients — close to home. Through The Network, these independent doctors come together to form a community of shared expertise and resources dedicated to advancing local cancer care and to delivering better patient outcomes. The Network provides practices with access to coordinated resources, best business practices, and the experience, infrastructure, and support of McKesson Corporation. This collaboration allows the providers in The Network to focus on the health of their patients, while McKesson focuses on the health of their practices. The Network is committed to the success of independent practices, everywhere.

About Ontada

Ontada® is an oncology real-world data and evidence, clinical education and provider technology business dedicated to transforming the fight against cancer. Part of McKesson Corporation, we support science through our data, technology, and channels, which accelerate innovation for life science companies, support the education of community oncology providers and advance patient care. Together with our partners, we improve the lives of cancer patients. For more information, visit ontada.com or follow @OntadaOncology.

View source version on businesswire.com: https://www.businesswire.com/news/home/20230215005115/en/